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To the Editor: Recently Garg et al.1 showed that reduced
glomerular filtration rate (GFR) (o60 ml/min) occurred in
12% of living kidney donors within 10 years of donation, on
the basis of studies measuring renal function using accepted
clearance methods. In the UK, targeted screening for reduced
renal function in various situations using the four-variable
modification of diet in renal disease equation to give
estimated GFR (eGFR) is being widely adopted.2 We recently
analyzed eGFR one year after living kidney donation in 72
consecutive donors at our centre between 2000 and 2005,
who had isotopically measured GFR 480 ml/min/1.73 m2
pre-donation (mean 103.4715.6 ml/min/1.73 m2). Mean ser-
um creatinine (7s.d.) pre-donation was 90.2 (715.1)
mmol/l. One year after donation, mean serum creatinine
was 118.6 (719.9) mmol/l, consistent with the studies in the
meta-analysis. However, this equated to a mean eGFR of 54.7
(79.26) ml/min/1.73 m2, resulting in 73.6% of donors with
an eGFR o60 ml/min/1.73 m2. A large proportion of living
donors will therefore be labelled as having chronic kidney
disease after donation. The difference between our data and
the meta-analysis presumably relates to the validity of the
modification of diet in renal disease formula in a healthy
population with near-normal renal function, rather than to a
true difference in renal function.3 This is an important
message for living donor transplantation. We now inform
donors that they may be identified as having chronic kidney
disease in the future, and we discuss the potential increased
cardiovascular risk.4 We agree that further research is
required to determine if reduced renal function in living
donors has the same implications as reduced renal function
in patients with diseased kidneys.
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Wan et al.1 highlight a number of important issues:
(a) Donors have a decrement in glomerular filtration rate
(GFR) after nephrectomy, and in many countries
donors who develop an estimated GFR less than
60 ml/min/1.73 m2 will be labeled as having chronic
kidney disease (CKD).
(b) A greater portion of donors will be labeled with CKD
by the abbreviated MDRD (modification of diet in
renal disease) formula compared to a more precise
measurement; in living donors, the MDRD formula
underestimated true GFR assessed by iothalamate.2
(c) A label of CKD might affect a donor and recipient
psychologically, and could affect a donor’s future
ability to obtain medical and life insurance.
(d) However, a label of CKD as assessed by GFR equations
is beneficial if it identifies a segment of donors at
substantial risk of future adverse events, prompting
the use of cardiorenal protective therapies to reduce
this risk.
(e) In the general population, the method by which CKD
mediates cardiovascular disease is uncertain.3 It may
relate to the coexistence of CKD with other known
cardiovascular risk factors such as hypertension,
diabetes, and smoking. CKD may be a marker for
the severity of these risk factors. CKD patients are
less likely than others to receive effective cardiovas-
cular medications. Finally, markers of inflammation,
uric acid, and other putative factors become exag-
gerated with a decrement in GFR, and might
contribute directly to adverse outcomes.
(f) Kidney donors develop a reduced GFR through a
different mechanism, and the prognostic significance
of a reduced estimated GFR in this population
requires future study.
(g) Given the possibility of increases in blood pressure
and reductions in GFR after donation,4,5 it remains
prudent to follow and screen all donors annually with
blood pressure, serum creatinine, and urine protein
measurements. Healthy lifestyle behaviors, which
minimize the risk of future cardiovascular and renal
sequelae, should also be emphasized.
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